Architecture and State Specific Productive Delivery Bottlenecks Determine Antibody Drug Conjugate Response and Causal Rescue

Architecture and State Specific Productive Delivery BottlenecksDetermine Antibody Drug Conjugate Response and Causal Rescue Bouchelit Mohammed El Amin Founder, SCIENTIFIC INTELLIGENCE DECISION · Frankfurt, Germany www.histamos.com | [email protected] Abstract Antibody–drug conjugate (ADC) development commonly begins with target-antigen expression, yet clinical and preclinical evidence shows that surface abundance alone cannot fully explain response. This paper proposes a compact causal framework in which ADC efficacy is determined by productive payload delivery and by the tumor state required to execute payload-induced injury. The central claim is not merely that intracellular processing matters, but that resistance can be localized to one or more causally limiting gates within a sequence comprising target accessibility, binding, internalization, intracellular trafficking, payload liberation, target-site exposure, pharmacodynamic engagement, and execution of cell death. A gate is considered causally limiting only if its selective repair, at substantially unchanged antigen expression, restores active payload exposure, pharmacodynamic effect, and tumor-cell killing in the predicted order. The framework also separates delivery-limited resistance from execution-limited resistance and from spatial or bystander-limited resistance. A matched architecture experiment using antigen-controlled tumor models is proposed to distinguish these mechanisms. If validated, this approach could support more informative ADC biomarkers, failure attribution, and rational rescue of otherwise viable target programs. 1. Background and Rationale ADCs require more than antigen recognition. After binding, an ADC may need productive internalization, endosomal and lysosomal trafficking, proteolytic or linker-dependent release, access of the active payload species to the relevant intracellular compartment, engagement of the payload target, and a tumor-cell state capable of translating that engagement into cytotoxicity. Prior studies have shown that intracellular processing rates can materially alter payload delivery, that released payload can correlate with ADC potency independently of target expression, and that lysosomal processing or transport can generate resistance even when target expression remains present [1–4]. Endocytic trafficking markers such as RAB5A have also shown predictive value for T-DM1 response [5]. These observations establish the biological importance of intracellular delivery; they do not, however, by themselves provide a causal rule for locating and repairing the dominant failure point in a given tumor–ADC pairing. 2. Hypothesis For a given tumor state, ADC architecture, and payload mechanism, therapeutic response is constrained by one or more causally limiting gates in the path from target access to functional payload execution. Surface antigen abundance is therefore necessary in many settings but is not sufficient to determine response. The relevant sequence can be represented as: target accessibility → productive binding → internalization → intracellular trafficking and lysosomal processing → formation of active payload species → target-site payload exposure → payload-target engagement → pharmacodynamic response → tumor-cell killing, with spatial penetration and bystander distribution contributing when relevant. A step should be called a causal bottleneck only when three conditions are met: the defect is reproducible; its selective repair increases active payload exposure and downstream pharmacodynamic activity while antigen abundance remains substantially unchanged; and re-blocking that same step removes the rescue. This definition prevents a low biomarker value or a simple correlation from being mislabeled as a mechanistic bottleneck. 3. Testable Predictions · An antigen-only model will be outperformed by a model that includes productive intracellular payload exposure and payload-specific pharmacodynamic readouts. · Among antigen-high but ADC-resistant tumors, at least two mechanistically distinct groups will emerge: delivery-limited tumors and execution-limited tumors. · In delivery-limited resistance, selective repair of the identified gate will increase active payload at its effective compartment, increase target engagement or a specific pharmacodynamic marker, and restore killing without materially increasing surface antigen. · Increasing delivery will not rescue tumors whose dominant failure lies downstream in payload sensitivity or cell-death execution. · In heterogeneous tumors, whole-tumor response may remain poor despite adequate target-cell delivery if spatial penetration, extracellular release, bystander propagation, or therapeutic-index constraints are limiting. 4. Decisive Experimental Design The proposed test uses antigen-matched tumor cell models, patient-derived organoids, or other qualified systems together with ADC architecture variants that isolate the suspected failure step as far as technically possible. Measurements should be time-resolved and should distinguish intact internalized ADC from active released payload. · Baseline measurements: surface antigen/accessibility, ADC binding, internalization, lysosomal arrival, active payload or catabolite, payload-target engagement, payload-specific pharmacodynamics, and viability. · Free-payload or orthogonal-delivery bypass: determines whether resistance lies upstream of payload action or persists after adequate intracellular payload exposure. · Gate-specific rescue: selectively repair the candidate limiting step while keeping antigen expression and ADC exposure as constant as possible. · Non-limiting control rescue: perturb a different step predicted not to be limiting. · Re-block experiment: reverse the rescued gate to test whether the recovered phenotype is lost again. · Spatial extension: in organoids or tumors, compare architectures with similar cell-autonomous delivery but different payload permeability, release topology, or bystander potential. The strongest support would be a prospectively specified sequence: unchanged antigen → repaired candidate gate → increased active payload at the target compartment → increased pharmacodynamic engagement → restored killing → loss of rescue after re-blocking. This is more informative than a correlation between trafficking and response. 5. Falsification and Limits The hypothesis should be rejected or narrowed if antigen abundance and accessibility remain sufficient predictors after direct measurement of active payload and pharmacodynamics; if candidate bottlenecks cannot be reproduced prospectively; if selective repair increases delivery without restoring pharmacodynamic effect or killing; or if non-specific perturbations rescue equally well. A resistant tumor that remains resistant after verified intracellular payload exposure and target engagement would favor an execution-limited explanation. Likewise, a model in which cell-autonomous killing is restored but organoid or tumor regression remains poor would indicate a dominant spatial, bystander, stromal, or therapeutic-index constraint rather than a purely intracellular delivery bottleneck. 6. Implications The practical value of this framework is not to replace antigen testing, but to place it within a causal delivery map. If validated, the approach could help distinguish target failure from architecture failure, identify when a linker, payload, trafficking requirement, or release topology is mismatched to the tumor state, and guide rational rescue without abandoning a biologically valid target. It may also motivate biomarker panels that measure productive payload delivery and pharmacodynamic execution rather than relying on surface expression alone. Conclusion ADC response should be treated as the output of a productive delivery-and-execution process rather than as a direct function of surface antigen abundance. The experimentally important claim is that the dominant failure point can be localized causally and, when technically addressable, selectively repaired. Demonstrating prospective bottleneck localization, gate-specific rescue, and re-blocking would convert a known descriptive feature of ADC biology into a testable rule for response prediction and architecture redesign. References 1. Maass KF, Kulkarni C, Betts AM, Wittrup KD. Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design. AAPS J. 2016;18(3):635–646. doi:10.1208/s12248-016-9892-3. 2. Li F, Emmerton KK, Jonas M, et al. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models. Cancer Res. 2016;76(9):2710–2719. doi:10.1158/0008-5472.CAN-15-1795. 3. Loganzo F, Sung M, Gerber HP. Mechanisms of Resistance to Antibody-Drug Conjugates. Mol Cancer Ther. 2016;15(12):2825–2834. doi:10.1158/1535-7163.MCT-16-0408. 4. Ríos-Luci C, García-Alonso S, Díaz-Rodríguez E, et al. Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity. Cancer Res. 2017;77(17):4639–4651. doi:10.1158/0008-5472.CAN-16-3127. 5. Engebraaten O, Yau C, Berg K, et al. RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer. Nat Commun. 2021;12:6427. doi:10.1038/s41467-021-26018-z. 6. Kinneer K, Meekin J, Tiberghien AC, et al. SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads. Clin Cancer Res. 2018;24(24):6570–6582. doi:10.1158/1078-0432.CCR-18-1300. Author Note This manuscript presents a mechanistic hypothesis and proposed experimental framework. It does not report new clinical or wet-laboratory efficacy data.